147751-16-4Relevant articles and documents
Facile Preparation of N-(sulfonyl)carbamates
Neustadt, Bernard R.
, p. 379 - 380 (1994)
N-(Sulfonyl)carbamates, useful N-nucleophiles in the Mitsunobu reaction, can be prepared readily by reaction of sulfonamides with chloroformates (or dicarbonates) catalyzed by 4-(dimethylamino)pyridine.
Identification of a novel orally bioavailable NLRP3 inflammasome inhibitor
Agarwal, Sameer,Pethani, Jignesh P.,Shah, Hardik A.,Vyas, Vismit,Sasane, Santosh,Bhavsar, Harsh,Bandyopadhyay, Debdutta,Giri, Poonam,Viswanathan, Kasinath,Jain, Mukul R.,Sharma, Rajiv
, (2020)
NLRP3 inflammasome mediated release of interleukin-1β (IL-1β) has been implicated in various diseases, including COVID-19. In this study, rationally designed alkenyl sulfonylurea derivatives were identified as novel, potent and orally bioavailable NLRP3 i
An unconventional sulfur-to-selenium-to-carbon radical transfer: Chemo-and regioselective cyclization of yne-ynamides
Dutta, Shubham,Prabagar,Vanjari, Rajeshwer,Gandon, Vincent,Sahoo, Akhila K.
supporting information, p. 1113 - 1118 (2020/03/11)
An uncommon sulfur → selenium → carbon radical transfer process is employed to develop an unprecedented selenyl radical-mediated regioselective cyclization of yne-tethered-ynamides. Density functional theory studies and HRMS experiments are used to establish a reactivity scale between thiyl and selenyl radicals. The unique features of this transformation include, (1) the chemoselective reactivity of RSe over RS, (2) regioselective RSe attack on alkyne over ynamide, (3) 5-exo-dig cyclization of yne-ynamide to unusual 4-selenyl-pyrroles, and (4) the green synthetic method. The reaction of methyldiselenide with yne-ynamides to methylselenopyrroles is also described.
HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS
-
Page/Page column 356; 357, (2018/03/25)
The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): (I), wherein L1, A, X1, X2, R1, R2, and R3 are described herein.